Anterix Inc. (ATEX)
Valuation Overview•Is Anterix Inc. Overvalued or Undervalued?
Market price has outpaced base-case intrinsic cash flows, pricing in significant future growth optimism.
High-quality fundamentals with a strong composite quality score of 88/100, backed by robust profitability and solvency.
Analysts remain cautious, with consensus price targets indicating limited room for upside expansion.
Verdict: Elite compounder with fortress-level fundamentals across every core pillar.
Wall Street is cautious, forecasting potential downside. However, capital return yields remain modest, driven predominantly by aggressive share repurchases.
ATEX exhibits elite business quality, driven by exceptional capital efficiency and highly lucrative margins. This is backed by a fortress balance sheet, holding significant net cash ($94M) and minimal debt risk.
The company is driving exceptional top-line expansion (50.2% 3Y CAGR) paired with stable bottom-line earnings. This growth is supported by elite operational efficiency, sustaining an impressive 1444.9% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $2.0M | +7.8% | +50.2% | +47.8% | +6.3% | |
| EBITDA | $19.9M | — | -39.9% | — | — | |
| Net Income | $18.5M | +897.0% | — | — | — | |
| EPS (Diluted) | $0.98 | +891.8% | — | — | — | |
| Free Cash Flow | $61.6M | +197.0% | — | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 100.0% | 97.6% | 98.5% | 25.0% |
| Operating Margin | 1444.9% | -358.7% | -1066.6% | -1552.6% |
| Net Margin | 1394.2% | 329.3% | -664.7% | -1358.7% |
| FCF Margin | 591.2% | 170.0% | -640.0% | -946.2% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $-0.56 | $-0.41 | +26.8% | ||
| Q1'26 | $-0.57 | $-0.35 | +38.6% | ||
| Q4'25 | $-0.65 | $-0.14 | +78.5% | ||
| Q3'25 | $-0.54 | $-0.48 | +11.1% | ||
| Q2'25 | $-0.43 | $-0.36 | +16.3% | ||
| Q1'25 | $-0.57 | $-0.46 | +19.3% | ||
| Q4'24 | $-0.59 | $-0.69 | -16.9% | ||
| Q3'24 | $-0.45 | $-0.84 | -86.7% |
Total return is +182.2% (1Y), outperforming the benchmark by +160.0%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +259.8% | +252.4% | — |
| 1Y | +182.2% | +160.0% | — |
| 3YCAGR | +36.2% | +12.3% | — |
| 5YCAGR | +4.7% | -7.1% | — |
| 10YCAGR | +13.7% | -0.3% | — |
The S&P 500 is at 30.6x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Anterix Inc. (ATEX) valuation, health, and returns.
Anterix Inc. is estimated to be overvalued under our discounted cash flow framework. relative multiples indicate the stock is Limited: Fair versus peers compared to industry peers. overvalued (implying -89.4% downside from DCF intrinsic value of $7.91)
Anterix Inc. has multiple valuation anchors: DCF Intrinsic Value: $7.91 | Peer Relative Fair Value: $79.66 | Wall Street Analyst Target: $69.00 (implying -13.7% upside). A convergence of these signals offers higher conviction.
Anterix Inc. displays excellent financial health with a composite quality score of 88/100, supported by a Piotroski F-Score of 5/9, Return on Invested Capital (ROIC) of -22.1%.
Anterix Inc. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Anterix Inc.'s current growth trajectory is Decelerating. The company achieved +7.8% 1Y revenue growth and +891.8% 1Y EPS growth, compared to its 3Y revenue CAGR of +50.2%.
Wall Street consensus is Buy based on 6 analysts, beating EPS expectations in 75% of recent quarters with a 6-quarter streak. The consensus price target represents a -13.7% change from current levels.
Investment risks for Anterix Inc. include: -37.5% 1-year max drawdown. Volatility risk is characterized by a beta of 1.23x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.